Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, EVNIN LUKE, holds the title of Director at Werewolf Therapeutics, Inc..
On 2026-06-01, the insider transacted 139,803 shares.The shares were transacted at a weighted average price of $0.46 per share, resulting in a total market-relevant value of $64K.
**Transaction:** sell of 139,803 shares by EVNIN LUKE (Director). **Strategic Implications (Investor Edge):** A director selling a substantial portion of their stake (over 20%) at a low price of $0.46 is a bearish signal, especially given the small market cap context. This suggests possible lack of confidence in near-term prospects or liquidity concerns. Investors should scrutinize upcoming catalysts and consider reducing positions. **Key Takeaways:** - Director sold 20.5% of his direct holdings in a single transaction. - Sale was not part of a pre-arranged 10b5-1 plan (not indicated in filing). - Price per share is low ($0.46), amplifying the signal of insider pessimism.
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.